Skye Bioscience SKYE
NASDAQ SKYE
$1.07 -0.03 (-2.29%)
At close: Nov 16, 2026 · 4:00 PM EST

Skye Bioscience (SKYE) EBITDA Margin (2013)

Updated

Analysis

Skye Bioscience (SKYE) EBITDA Margin (2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn 36.69%
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn 32.68%
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn 46.88%
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn 40.60%
5 Novartis Ag 310.90 Bn 284.14 Bn - -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn 39.77%
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn 46.62%
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn 50.63%
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn 42.49%
10 Skye Bioscience 5.38 Mn -52.34 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Oct 31, 2013 -3.03%
Jul 31, 2013 5.04%
Apr 30, 2013 6.85%
Jan 31, 2013 -9.46%
API Access

Skye Bioscience EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SKYE&period=max&api_key=YOUR_API_KEY